SLC5A2 and type 2 diabetes mellitus: The treatment for T2D before BS were metformin (48%), insulin (16%), glucagon-like peptide-1 receptor agonists (GLP-1AR), sodium-glucose cotransporter-2 inhibitors (iSGLT2), or peroxisome proliferator-activated receptor gamma (PPARγ) agonists (12%); the rest (24%) were in diet alone.